Skip to content
Home » Johnson & Johnson Just Cut an Entire Division. Is It Still a Buy?

Johnson & Johnson Just Cut an Entire Division. Is It Still a Buy?

    Johnson & Johnson (NYSE: JNJ) plans to cut or dramatically scale down its vaccine and infectious disease division. The move comes roughly around the same time the company finalizes the spinoff of its consumer health division, called Kenvue. Given these changes, some investors have reason to question the behemoth's growth prospects, as J&J can no longer expect to boost its revenue with new commercialized vaccines or through new personal care products.

    Read full NASCAR article on Yahoo Sports

    Read all NASCAR articles